CompletedNot Applicable

Comparative Study of Diagnostic and Prognosis Biomarkers of Prostate Cancer in Liquid Biopsy (HOPE)

France80 participantsStarted 2022-05-04

Plain-language summary

Constitution of a biological collection within the framework of the establishment of a diagnostic, prognostic and active surveillance test for prostate cancer from long non-coding RNA biomarkers, in 3 cohorts of patients, with cancer of the prostate, with suspected cancer without biopsy confirmation or with prostatic hyperplasia and healthy donors. This biological collection will also be used as a support for further researches on the identification of biomarkers and genetic markers to improve the prognosis and diagnostic management of patients with prostate pathologies.

Who can participate

Age range50 Years – 70 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. / Patient with suspected prostate cancer or prostatic hyperplasia with a PSA level ≥ 4 ng / ml
✓. / Patient diagnosed by prostate MRI in the course of treatment
✓. / No infectious episode in the week before the visit (in particular no urinary tract infection) documented by dipstick and absence of fever
✓. / Information of the patient and signature of informed consent or his legal representative.
✓. / Participant affiliated to a social security scheme
✓. / Male from 50 to 70 years old
✓. / PSA level \< 4 ng / mL
✓. / No infectious episode in the week before the visit (in particular no urinary tract infection), documented by dipstick and the absence of fever

What they're measuring

Extracting extravesicular particles and RNA from urine fluids

Timeframe: Baseline

Trial details

NCT IDNCT05141383

SponsorInstitut Curie

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-09-03

View on ClinicalTrials.gov More Prostate Cancer trials